Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Targeted Therapy × gilteritinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Leukemia, Myeloid, Acute 17 Targeted Therapy 1 Recurrence 1 Neoplasm, Residual 1 Myelodysplastic-Myeloproliferative Diseases 1 Lung Neoplasms 1 Leukemia, Myelomonocytic, Chronic 1 Leukemia, Myeloid 1 Infections 1 Hematologic Neoplasms 1 Disease 1 Carcinoma, Non-Small-Cell Lung 1

Interventions

venetoclax 1 ruxolitinib 1 olutasidenib 1 gilteritinib 1 Cytarabine 1 Cladribine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07032727 2025-12-15

Olutasidenib Combined With Co-targeted Therapy in Relapsed or Refractory IDH1-mutated Myeloid Malignancies Harboring Activated Signaling Pathway Mutations

M.D. Anderson Cancer Center

Phase 2 Recruiting

Targeted Therapy

Data powered by HemOnc (CC BY 4.0) Colophon ⚡